News

\r\n The old traders’ adage “better to travel than arrive” has been true in 2017. Last year wa...
\r\n President Donald Trump signed on 28 March 2017 an executive order to unravel former President B...
\r\n According to some scientists, the fingerprint of human-caused climate change has been found on ...
\r\n Australia’s federal government has announced it will ratify and implement the OPCAT Treaty, O...
\r\n Nurses and teachers are among those bearing the brunt of a debt crisis rooted in the mistaken b...

Follow us

Articles

PHARMACEUTICAL INDUSTRY ISSUE DISCUSSED AT THE EUROPEAN BUSINESS SUMMIT 2014

Europe's pharmaceutical industry employs around 700,000 people and stands for 17% of Europe's investments in research and development. The industry is trying to increase the EU's industrial GDP target and the EU should make this goal a priority to keep a sustainable environment for the industry,  as representatives stated at the European Business Summit 2014 on Thursday 15 May.

Paola Testori Coggi, director-general of DG Health and Consumers (SANCO), said that the Commission has made excellent proposals for a new regulation for the pharmaceutical industry, but that the proposals are sometimes prevented by the Council and member states. As she told pharmaceutical manufactures, health ministers often have a weak voice in government and most of them are keen to cut healthcare costs, even though they usually argue that health is an investment for their countries.

The pharmaceutical industry has helped EU citizens live longer lives, but in order to also keep making them live longer and healthier lives, member states need to have a fully integrated and sustainable healthcare approach.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Generic medicines Association (EGA) jointly presented proposals to the Summit for an integrated EU industrial policy for the pharmaceutical sector.

It is important to recognize that medicines are essential to improve patient outcomes and equity of access to healthcare across Europe. It is necessary to support a more sustainable and predictable business environment to incentivize the pharmaceutical industry to invest in bringing better and more cost-effective treatments to patients and  improve an environment that will make the EU an attractive global environment for pharmaceutical research and manufacturing.

 

The gLAWcal Team

Thursday, June 5, 2014

(Source: Pharma Times)

This news has been realized by gLAWcal—Global Law Initiatives for Sustainable Development in collaboration with the University Institute of European Studies (IUSE) in Turin, Italy and the University of Piemonte Orientale, Novara, Italy which are both beneficiaries of the European Union Research Executive Agency IRSES Project “Liberalism in Between Europe And China” (LIBEAC) coordinated by Aix-Marseille University (CEPERC). This work has been realized in the framework of Workpackages 4, coordinated by University Institute of European Studies (IUSE) in Turin, Italy.